Nanocrystallization Improves the Solubilization and Cytotoxic Effect of a Poly (ADP-Ribose)-Polymerase-I Inhibitor

Olaparib (OLA) is an anticancer agent that acts by inhibiting the poly (ADP-ribose)-polymerase-I (PARP-I). Due to its low solubility and low permeability, it has been placed as a BCS Class-IV drug and hence its clinical use is limited. In this study, we develop the nanocrystals of OLA as a way to im...

Descripción completa

Detalles Bibliográficos
Autores principales: Alali, Amer S., Kalam, Mohd Abul, Ahmed, Mohammed Muqtader, Aboudzadeh, M. Ali, Alhudaithi, Sulaiman S., Anwer, Md. Khalid, Fatima, Farhat, Iqbal, Muzaffar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696361/
https://www.ncbi.nlm.nih.gov/pubmed/36432955
http://dx.doi.org/10.3390/polym14224827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696361/
https://www.ncbi.nlm.nih.gov/pubmed/36432955
http://dx.doi.org/10.3390/polym14224827

Ejemplares similares